Management of Adverse Effects of Second-generation Antipsychotics in Youth
Marie Raffin,Marianna Gianitelli,Angèle Consoli,Olivier Bonnot,Marie-Line Menard,Florence Askenazy,Claudine Laurent,David Cohen +7 more
TLDR
Short-term and long-term adverse effects of SGAs in youth populations are exposed and management recommendations for major adverse effects are provided to aid clinicians in making treatment decisions.Abstract:
Second-generation antipsychotics (SGAs) have been proven effective in treating several psychiatric conditions in children and adolescents. These atypical antipsychotic medications are being used with increasing frequency in Europe, the U.S., and Canada. We aim to expose short-term and long-term adverse effects (AEs) of SGAs in youth populations and to provide management recommendations for major adverse effects. These proposals are based on (1) an in-depth literature review of both short- and long-term studies on the use of SGAs in youth; (2) our own clinical experience in managing such treatment in this population; and (3) the work of the Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA). AEs are frequent in youth treated with SGAs, and include primarily weight gain, metabolic and hormonal changes, somnolence, extrapyramidal syndrome, and QT modifications. However, frequency and type of AE vary according to compound, and each compound’s AE profile is specific. Acknowledgment of these distinct profiles should aid clinicians in making treatment decisions. After an SGA is prescribed, routine monitoring of AEs is recommended, and should an AE occur, clinical management recommendations should be followed. To date, there are no clinically validated monitoring recommendations.read more
Citations
More filters
Journal Article
Re: Prolactin levels and adverse events in patients treated with risperidone [8] (multiple letters)
Journal ArticleDOI
Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents
TL;DR: All adolescents experienced AE, with significant weight gain being observed in all patients who completed the 12-week follow-up, and further evidence for the necessity of national safety guidelines for AP prescription in the pediatric population is provided.
Journal ArticleDOI
Pediatric Antipsychotic Use and Outcomes Monitoring.
TL;DR: An example of the use of the HealthTracker in the CIPPRD is provided to demonstrate how it can be used for ATP-related outcome monitoring in complex neurodisability within routine clinical practice.
Journal ArticleDOI
Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: Results of a multicenter naturalistic study (ETAPE).
Marie-Line Menard,Susanne Thümmler,Marianna Giannitelli,Coralie Cruzel,Olivier Bonnot,David Cohen,Florence Askenazy,Michel Boublil,Jean Chambry,Dorothée Charvet,Mona Cseterky,Eric Fontas,Pierre Fourneret,Ludovic Gicquel,Bernard Kabuth,Bernard Leroy,Fanny Maria,Pamela Moceri,Nadege Parassol-Girard,Brigitte Ravis,Jean-Philippe Raynaud,Jean-François Roche,Thierry Rochet +22 more
TL;DR: ETAPE study highlights a high incidence rate of AE in children treated with AP, and a careful and continuous clinical and biological monitoring is required to adapt treatment decisions based on benefice-risk-analysis.
Journal ArticleDOI
Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: a French multicentre naturalistic study protocol (ETAPE)
Marie-Line Menard,Susanne Thümmler,Marianna Giannitelli,Bertrand Olliac,Olivier Bonnot,David Cohen,Florence Askenazy +6 more
TL;DR: This study will enable better characterisation of the prescription of AP drugs in an AP-naïve paediatric population named Etude de la Tolérance des AntiPsychotique chez l'Enfant (ETAPE), and help to develop quality standards and recommendations for monitoring AE during the prescriptions of AP.
References
More filters
Journal ArticleDOI
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes Response to consensus statement
TL;DR: The ADA concluded that aripiprazole and ziprasidone have no effect on the risk of diabetes, solely based on data from clinical trials that did not include these two drugs in epidemiological studies.
Journal ArticleDOI
Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Peter B. Jones,Thomas R. E. Barnes,Linda Davies,Graham Dunn,Helen Lloyd,Karen P. Hayhurst,Robin M. Murray,A. Markwick,Shôn Lewis +8 more
TL;DR: In people with schizophrenia whose medication is changed for clinical reasons, there is no disadvantage across 1 year in terms of quality of life, symptoms, or associated costs of care in using FGAs rather than nonclozapine SGAs.
Journal ArticleDOI
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
René S. Kahn,W. Wolfgang Fleischhacker,Han Boter,Michael Davidson,Yvonne Vergouwe,I. P. M. Keet,Mihai Dumitru Gheorghe,Janusz K. Rybakowski,Silvana Galderisi,Jan Libiger,Martina Hummer,Sonia Dollfus,Juan J. López-Ibor,Luchezar Hranov,Wolfgang Gaebel,Joseph Peuskens,Nils Lindefors,Anita Riecher-Rössler,Diederick E. Grobbee +18 more
TL;DR: This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia is achievable, for at least 1 year, but it cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement.
Journal ArticleDOI
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Christoph U. Correll,Peter Manu,Vladimir Olshanskiy,Barbara Napolitano,John M. Kane,Anil K. Malhotra +5 more
TL;DR: Weight gain and changes in lipid and metabolic parameters in patients without prior antipsychotic medication exposure are studied and mean levels increased significantly for total cholesterol, triglycerides, and non-high-density lipoprotein cholesterol.